Status:
COMPLETED
Vulvovaginal Graft Versus Host Disease (VV-GVHD) in Women Who Underwent Transplantation Before and After Menarche
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Graft-vs-Host Disease
Eligibility:
FEMALE
18-70 years
Brief Summary
The study will evaluate the prevalence and characteristics of vulvovaginal graft versus host disease (VV- GVHD) in patients who underwent hematopoietic stem cell transplantation (HSCT) as girls or ado...
Detailed Description
The phenomenon of vulvovaginal graft versus host disease (VV-GVHD) following hematopoietic stem cell transplantation (HSCT) was first described in 1982 \[Corson\]. It is characterized by vulvovaginal ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients who underwent allogeneic HSCT before the age of 18, who are 18 years or older at the time of the study and who are willing to participate in the study .
- Exclusion Criteria:
- not able to comply with the study
Exclusion
Key Trial Info
Start Date :
December 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT01512498
Start Date
December 1 2012
End Date
December 1 2018
Last Update
February 21 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pediatric Hematology Oncology Department, Rambam Hospital
Haifa, Israel
2
Hadassah University Hospital
Jerusalem, Israel, 91240